Pharma_88
☆    

India,
2020-11-27 13:51
(300 d 20:51 ago)

Posting: # 22089
Views: 659
 

 Orlistat EMA [Design Issues]

Dear All,

This is regarding Orlistat for EMA submission. We have US product specific guidance available but I am unable to find EMA guidance (most probably its not there).

My question is whether is it required to add third arm (The reference product at 2 x 60 mg or 120 mg tid) as per US OGD for EMA? whether regualotry will accept this design as per FDA or 2WCO is sufficient (The test & reference product at 60 mg tid as crossover)?

thanks.
Activity
 Admin contact
21,694 posts in 4,535 threads, 1,541 registered users;
online 6 (1 registered, 5 guests [including 2 identified bots]).
Forum time: Friday 11:42 CEST (Europe/Vienna)

Tortured data will confess to anything.    Fredric Menger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5